Publications by authors named "R Garro"
Background: The heterogeneous clinical presentation of graft microvascular inflammation poses a major challenge to successful kidney transplantation. The effect of microvascular inflammation on allograft outcomes is unclear.
Methods: We conducted a cohort study that included kidney-transplant recipients from more than 30 transplantation centers in Europe and North America who had undergone allograft biopsy between 2004 and 2023.
Article Synopsis
- Donor-derived cell-free DNA (dd-cfDNA) is an innovative noninvasive biomarker being studied for its ability to detect kidney allograft injuries, such as rejection.
- In a study involving 2,882 kidney transplant recipients, high levels of dd-cfDNA were strongly linked to various types of allograft rejection, and it significantly improved prediction models beyond what's typically used in patient monitoring.
- The study, which included diverse cohorts, reinforced that measuring dd-cfDNA could enhance the detection of even subtle rejection in stable patients, providing valuable insights for better transplant management.
Background: BK polyomavirus (BKV) DNAemia is a challenging infectious complication after kidney transplant (KT). Reduction of immunosuppression is the mainstay of management, and tacrolimus is often the first immunosuppressive medication adjusted upon the diagnosis of BKV DNAemia. This study aimed to evaluate the impact of a new institutional protocol with lower target tacrolimus levels on BKV DNAemia, allograft rejection, and de novo donor-specific antibodies (dnDSA) among pediatric KT recipients.
View Article and Find Full Text PDFBackground: Antibody-mediated rejection (AMR) is a major cause of kidney allograft loss. There is a paucity of large-scale pediatric-specific data regarding AMR treatment outcomes.
Methods: Data were obtained from 14 centers within the Pediatric Nephrology Research Consortium.
Article Synopsis
- * This study evaluates whether combining plasmapheresis with rituximab can effectively prevent the recurrence of FSGS in kidney transplant patients.
- * The combination therapy aims to offer a new treatment approach for recurrent FSGS, which currently has limited options and lacks standardized guidelines.